
Please try another search
A month has gone by since the last earnings report for Pacific Biosciences of California (PACB). Shares have lost about 18.1% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Pacific Biosciences due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Pacific Biosciences Reports Break-Even Earnings in Q4
Pacific Biosciences reported fourth-quarter 2019 break-even earnings per share versus the Zacks Consensus Estimate of a loss of 16 cents. The company had reported a loss of 21 cents in the year-ago quarter.
Revenues of the company totaled $27.93 million, which outpaced the Zacks Consensus Estimate by 9.8%. Revenues improved 43% from the year-ago quarter’s tally.
Segmental Analysis
Product Revenues: At this segment, revenues amounted to $24.6. million, up 49.4% from the prior-year quarter’s tally.
Service and Other Revenues: At this segment, revenues came in at $3.4 million, up 9.4% year over year.
Margins
Gross profit in the fourth quarter of 2019 was $12.9 million, up significantly from the year-ago $5.7 million. Gross margin was 46.3% of total revenues, improving significantly from the year-ago quarter’s 29.4%.
Research and development expenses increased 12.2% to $14.3 million in the quarter. Further, sales, general and administrative expenses dropped 17.6% to $16.6 million.
Operating expenses totaled $30.8 million, down 15.2% year over year.
How Have Estimates Been Moving Since Then?
Analysts were quiet during the last two month period as none of them issued any earnings estimate revisions.
VGM Scores
At this time, Pacific Biosciences has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with an F. Following the exact same course, the stock was allocated a grade of F on the value side, putting it in the lowest quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Pacific Biosciences has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Consumers are feeling the pinch from inflation every time they go to the grocery store. Money is a zero-sum game; as disposable income and buying power erodes, consumers are...
In a striking reversal of fortunes, equities in developed markets ex-US are now leading the major asset classes in 2025 while US shares are posting a modest loss year to date,...
US index futures broke lower after Marvell Technology's earnings missed. Nasdaq and S&P 500 are now testing key support zones. Meanwhile, Amazon, Oracle, Tesla and...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.